We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Bedside Test to Protect Newborns from Life-Threatening Illnesses

By LabMedica International staff writers
Posted on 04 Jan 2024
Print article
Image: A research project aiming to protect babies from deadly infection has reached a major milestone (Photo courtesy of Shutterstock)
Image: A research project aiming to protect babies from deadly infection has reached a major milestone (Photo courtesy of Shutterstock)

Group B Streptococcus (GBS), a bacterial strain, is the leading cause of severe infections in newborns in the UK. Around one in four pregnant women in the UK are carriers of GBS, often unknowingly, and during childbirth, there's a 50% chance of transmitting the bacteria to the baby. While most exposed infants remain healthy, approximately one in 1,750 will develop early-onset GBS infections, including sepsis, pneumonia, or meningitis, which can have severe consequences. The UK currently employs a 'risk factor-based screening' approach, providing antibiotics during labor to women identified with GBS during pregnancy or those with a previous baby affected by GBS. However, this strategy fails to detect many GBS carriers, with about 65% of early-onset GBS infections in newborns occurring in babies whose mothers had no identified risk factors. Now, a research project is examining the potential of a rapid bedside test for safeguarding newborns from life-threatening illnesses transmitted during birth.

The GBS3 study, conducted by the University of Nottingham (Nottingham, UK), has so far recruited over 1,100 pregnant women across the UK. The research aims to determine whether universally screening pregnant women for GBS can reduce the incidence of newborn infections. The study compares two methods: a test during a prenatal visit around 36 weeks of pregnancy and a quick bedside test conducted as labor begins that delivers results in about 40 minutes. Upon positive results, antibiotics are administered to protect the newborn from potential illness. The study, set to recruit until March 2024, is being conducted in 71 hospitals across England, Wales, and Scotland, out of which 17 sites are equipped for rapid testing.

“This is the first trial of its kind in the world and the results will help to determine whether routine testing should be introduced in the UK,” said Mr. Sachchidananda Maiti, consultant obstetrician, who is leading the study in the North Manchester maternity unit. “Identifying women with GBS with greater accuracy and treating them with antibiotics at the optimum time, could prevent approximately 40 newborn deaths and 25 cases of disability in the UK each year.”

Related Links:
University of Nottingham 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.